Developments in the systemic treatment of metastatic cervical cancer

Cancer Treatment Reviews

Volumn 39, Issue 5, 2013, Pages 430-443

  Mountzios, Giannis ^a,b   Soultati, Aspasia ^a   Pectasides, Dimitrios ^b   Pectasides, Eirini ^b   Dimopoulos, Meletios A ^b   Papadimitriou, Christos A ^b  

^a IASO GENERAL HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Cervical cancer; Chemotherapy; Metastatic; Prognostic and predictive markers; Systemic therapy; Targeted therapy; Toxicity

Indexed keywords

CAPECITABINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; ESORUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; IDARUBICIN; IFOSFAMIDE; IPROPLATIN; IRINOTECAN; MESNA; METHOTREXATE; MITOXANTRONE; NAVELBINE; OXALIPLATIN; PACLITAXEL; PEMETREXED; PIRARUBICIN; TENIPOSIDE; TOPOTECAN; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE; VINDESINE;

ALOPECIA; ANEMIA; ANGIOGENESIS; ANOREXIA; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CHEMORADIOTHERAPY; COMA; CONTINUOUS INFUSION; DELIRIUM; DIARRHEA; DISEASE COURSE; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG SAFETY; EXCISION REPAIR; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; GRANULOCYTOPENIA; HEMORRHAGIC CYSTITIS; HUMAN; INFECTION; KIDNEY FAILURE; LEUKOPENIA; LIVER TOXICITY; LYMPH NODE METASTASIS; MEDICAL HISTORY; MONOTHERAPY; MUCOSA INFLAMMATION; MULTICENTER STUDY (TOPIC); NAUSEA; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; OTOTOXICITY; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; SKIN TOXICITY; SOMNOLENCE; STOMATITIS; SURVIVAL RATE; SYSTEMIC THERAPY; THROMBOCYTOPENIA; TIME TO TREATMENT; TREATMENT RESPONSE; UPREGULATION; UTERINE CERVIX CANCER; VOMITING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIALS, PHASE III AS TOPIC; FEMALE; HUMANS; NEOPLASM METASTASIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; UTERINE CERVICAL NEOPLASMS;

EID: 84876969128     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2012.05.009     Document Type: Review

References (152)

1. Kamangar F., Dores G.M., Anderson W.F. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006, 24:2137-2150.
2. Mathers C, Boerma T, Ma Fat D. The global burden of disease: 2004 update. World Health Organization, Geneva, Switzerland, 2008. Available from: http://www.who.int/healthinfo/global_burden_disease/GBD_report_2004update_full.
3. Burns A., Sanghvi H., Lu R., Gaffikin L., Blumethal P.D. Saving women's lives from cervical cancer. Lancet 2011, 377:1318.
4. Ries L.A.G., Harkins D., Krapcho M., et al. SEER cancer statistics review, 1975-2003 2006, National Cancer Institute, Bethesda, Md.
5. Eifel P.J. Concurrent chemotherapy and radiation therapy as the standard of care for cervical cancer. Nat Clin Pract Oncol 2006, 3(5):248-255.
6. Movva S., Rodriguez L., Arias-Pulido H., Verschraegen C. Novel chemotherapy approaches for cervical cancer. Cancer 2009, 115(14):3166-3180.
7. Dueñas-González A., Cetina L., Coronel J., Martínez-Baños D. Pharmacotherapy options for locally advanced and advanced cervical cancer. Drugs 2010, 70(4):403-432.
8. Rodríguez Villalba S., Díaz-Caneja Planell C., Cervera Grau J.M. Current opinion in cervix carcinoma. Clin Transl Oncol 2011, 13(6):378-384.
9. Bonomi P., Blessing J.A., Stehman F.B., DiSaia P.J., Walton L., Major F.J. Randomized trial of 3 cisplatin dose schedules in squamous-cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 1985, 3:1079-1085.
10. Thigpen J.T., Blessing J.A., DiSaia P.J., et al. A randomized comparison of rapid versus prolonged (24hr) infusion of cisplatin in therapy of squamous cell carcinoma of the uterine cervix: a Gynecologic Oncology Group study. Gynecol Oncol 1989, 32:198-202.
11. Morris M., Gershenson D.M., Burke T.W., et al. A phase II study of carboplatin and cisplatin in advanced or recurrent squamous carcinoma of the uterine cervix. Gynecol Oncol 1994, 53:234-238.
12. Arseneau J., Blessing J.A., Stehman F.B., McGehee R. A phase II study of carboplatin in advanced squamous cell carcinoma of the cervix (a Gynecologic Oncology Group study). Invest New Drugs 1986, 4:187-191.
13. Weiss G.R., Green S., Hannigan E.V., et al. A phase II trial of carboplatin for recurrent or metastatic squamous carcinoma of the uterine cervix: a Southwest Oncology Group study. Gynecol Oncol 1990, 39(3):332-336.
14. McGuire W.P., Blessing J.A., Hatch K., DiSaia P.J. A phase II study of CHIP in advanced squamous cell carcinoma of the cervix (a Gynecologic Oncology Group study). Invest New Drugs 1986, 4(2):181-186.
15. Lira-Puerto V., Silva A., Morris M., et al. Phase II trial of carboplatin or iproplatin in cervical cancer. Cancer Chemother Pharmacol 1991, 28(5):391-396.
16. Long H.J. Management of metastatic cervical cancer: review of the literature. J Clin Oncol 2007, 25:2966-2974.
17. Tanioka M., Katsumata N., Yonemori K., et al. Second platinum therapy in patients with uterine cervical cancer previously treated with platinum chemotherapy. Cancer Chemother Pharmacol 2011, 68(2):337-342.
18. Kudelka A.P., Winn R., Edwards C.L., et al. Activity of paclitaxel in advanced or recurrent squamous cell cancer of the cervix. Clin Cancer Res 1996, 2(8):1285-1288.
19. Kudelka A.P., Winn R., Edwards C.L., et al. An update of a phase II study of paclitaxel in advanced or recurrent squamous cell cancer of the cervix. Anticancer Drugs 1997, 8(7):657-661.
20. Wallace H.J., Hreshchyshyn M.M., Wilbanks G.D., Boronow R.C., Fowler W.C., Blessing J.A. Comparison of the therapeutic effects of adriamycin alone versus adriamycin plus vincristine versus adriamycin plus cyclophosphamide in the treatment of advanced carcinoma of the cervix. Cancer Treat Rep 1978, 62(10):1435-1441.
21. Eifel P.J. Concurrent chemotherapy and radiation therapy as the standard of care for cervical cancer. Nat Clin Pract Oncol 2006, 3(5):248-255.
22. Chauvergne J., Fumoleau P., Cappelaere P., et al. Phase II study of pirarubicin (THP) in patients with cervical, endometrial and ovarian cancer: study of the Clinical Screening Group of the European Organization for Research and Treatment of Cancer (EORTC). Eur J Cancer 1993, 29A(3):350-354.
23. Muss H.B., Sutton G.P., Bundy B., Hatch K.D. Mitoxantrone (NSC 301739) in patients with advanced cervical carcinoma. A phase II study of the Gynecologic Oncology Group. Am J Clin Oncol 1985, 8(4):312-315.
24. van der Burg M.E., Monfardini S., Guastalla J.P., de Oliveira C., Renard J., Vermorken J.B. Phase II study of weekly 40-epidoxorubicin in patients with metastatic squamous cell cancer of the cervix: an EORTC Gynaecological Cancer Cooperative Group study. Eur J Cancer 1992, 29A(1):147-148.
25. Hakes T.B., Dougherty J.B., Raymond V. Phase II study of idarubicin in advanced cervical carcinoma. Am J Clin Oncol 1986, 9(3):262-263.
26. McGuire W.P., Blessing J.A., Yordan E., Beecham J. Phase II study of esorubicin (40-deoxydoxorubicin) in advanced or metastatic squamous carcinoma of the uterine cervix: a Gynecologic Oncology Group study. Invest New Drugs 1989, 7(2-3):235-238.
27. Pectasides D., Kamposioras K., Papaxoinis G., Pectasides E. Chemotherapy for recurrent cervical cancer. Cancer Treat Rev 2008, 34:603-613.
28. Smith J.P., Rutledge F., Burns B.C., Soffar S. Systemic chemotherapy for carcinoma of the cervix. Am J Obstet Gynecol 1967, 97(6):800-807.
29. Sutton G.P., Blessing J.A., Adcock L., Webster K.D., DeEulis T. Study of ifosfamide and mesna in patients with previously treated carcinoma of the cervix. A Gynecologic Oncology Group study. Invest New Drugs 1989, 7(4):341-343.
30. Sutton G.P., Blessing J.A., McGuire W.P., Patton T., Look K.Y. Phase II trial of ifosfamide and mesna in patients with advanced or recurrent squamous carcinoma of the cervix who had never received chemotherapy: a Gynecologic Oncology Group study. Am J Obstet Gynecol 1993, 168(3 Pt 1):805-807.
31. Meanwell C.A., Mould J.J., Blackledge G., et al. Phase II study of ifosfamide in cervical cancer. Cancer Treat Rep 1986, 70:727-730.
32. Muderspach L.I., Blessing J.A., Levenback C., Moore J.L. A Phase II study of topotecan in patients with squamous cell carcinoma of the cervix: a gynecologic oncology group study. Gynecol Oncol 2001, 81(2):213-215.
33. Bookman M.A., Blessing J.A., Hanjani P., Herzog T.J., Andersen W.A. Topotecan in squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol 2000, 77(3):446-449.
34. Irvin W.P., Price F.V., Bailey H., et al. A phase II study of irinotecan (CPT-11) in patients with advanced squamous cell carcinoma of the cervix. Cancer 1998, 82(2):328-333.
35. Lhommé C., Fumoleau P., Fargeot P., et al. Results of a European Organization for Research and Treatment of Cancer/Early Clinical Studies Group phase II trial of first-line irinotecan in patients with advanced or recurrent squamous cell carcinoma of the cervix. J Clin Oncol 1999, 17(10):3136-3142.
36. Look K.Y., Blessing J.A., Levenback C., Kohler M., Chafe W., Roman L.D. A phase II trial of CPT-11 in recurrent squamous carcinoma of the cervix: a gynecologic oncology group study. Gynecol Oncol 1998, 70:334-338.
37. Takeuchi S., Dobashi K., Fujimoto S., et al. [A late phase II study of CPT-11 on uterine cervical cancer and ovarian cancer. Research Groups of CPT-11 in Gynecologic Cancers]. Gan To Kagaku Ryoho 1991, 18:1681-1689.
38. Morris M., Brader K.R., Burke T.W., Levenback C.F., Gershenson D.M. A phase II study of prolonged oral etoposide in advanced or recurrent carcinoma of the cervix. Gynecol Oncol 1998, 70(2):215-218.
39. Rose P.G., Blessing J.A., Van Le L., Waggoner S. Prolonged oral etoposide in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study. Gynecol Oncol 1998, 70(2):263-266.
40. Pfeiffer P., Cold S., Bertelsen K., Panduro J., Sandberg E., Rose C. Teniposide in recurrent or advanced cervical carcinoma: a phase II trial in patients not previously treated with cytotoxic therapy. Gynecol Oncol 1990, 37(2):230-233.
41. Morris M., Brader K.R., Levenback C., et al. Phase II study of vinorelbine in advanced and recurrent squamous cell carcinoma of the cervix. J Clin Oncol 1998, 16(3):1094-1098.
42. Sutton G.P., Blessing J.A., Barnes W., Ball H. Study of vinblastine in previously treated squamous carcinoma of the cervix. A Gynecologic Oncology Group study. Am J Clin Oncol 1990, 13(6):470-471.
43. Kavanagh J.J., Copeland L.J., Gershenson D.M., Saul P.B., Wharton F.N., Rutledge F.N. Continuous-infusion vinblastine in refractory carcinoma of the cervix: a phase II trial. Gynecol Oncol 1985, 21(2):211-214.
44. Miller D.S., Blessing J.A., Bodurka D.C., Bonebrake A.J., Schorge J.O. Evaluation of pemetrexed (Alimta, LY231514) as second line chemotherapy in persistent or recurrent carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol 2008, 110:65-70.
45. Lorusso D., Ferrandina G., Pignata S., et al. Evaluation of pemetrexed (Alimta, LY231514) as second-line chemotherapy in persistent or recurrent carcinoma of the cervix: the CERVIX 1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group. Ann Oncol 2010, 21:61-66.
46. Look K.Y., Blessing J.A., Muss H.B., Partridge E.E., Malfetano J.H. 5- fluorouracil and low-dose leucovorin in the treatment of recurrent squamous cell carcinoma of the cervix. A phase II trial of the Gynecologic Oncology Group. Am J Clin Oncol 1992, 15(6):497-499.
47. Look K.Y., Blessing J.A., Gallup D.G., Lentz S.S. A phase II trial of 5- fluorouracil and high-dose leucovorin in patients with recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Am J Clin Oncol 1996, 19(5):439-441.
48. Schilder R.J., Blessing J.A., Morgan M., Mangan C.E., Rader J.S. Evaluation of gemcitabine in patients with squamous cell carcinoma of the cervix: a phase II study of the gynecologic oncology group. Gynecol Oncol 2000, 76(2):204-207.
49. de Palo G.M., Bajetta E., Luciani L., Musumeci R., Di Re F., Bonadonna G. Methotrexate (NSC-740) and bleomycin (NSC- 125066) in the treatment of advanced epidermoid carcinoma of the uterine cervix. Cancer Chemother Rep 1973, 57(4):429-435.
50. Hakes T., Nikrui M., Magill G., Ochoa M. Cervix cancer: treatment with combination vincristine and high doses of methotrexate. Cancer 1979, 43(2):459-464.
51. Lorvidhaya V., Chitapanarux I., Phromratanapongse P., et al. Phase II study of capecitabine (Ro 09-1978) in patients who have failed first line treatment for locally advanced and/or metastatic cervical cancer. Gan to kagaku ryoho 2010, 37(7):1271.
52. Hirai Y., Katsumat N., Kamiura S., et al. Phase II study of S-1 in patients with advanced or recurrent cervical cancer. ASCO Meeting Abstracts 2008, 26:5514.
53. Katsumata N., Hirai Y., Kamiura S., et al. Phase II study of S-1, an oral fluoropyrimidine, in patients with advanced or recurrent cervical cancer. Ann Oncol 2011, 22(6):1353-1357.
54. Weiss G.R., Green S., Hannigan E.V., et al. A phase II trial of cisplatin and 5-fluorouracil with allopurinol for recurrent or metastatic carcinoma of the uterine cervix: a Southwest Oncology Group trial. Gynecol Oncol 1990, 37:354-358.
55. Kaern J., Tropé C., Abeler V., Iversen T., Kjørstad K. A phase II study of 5-fluorouracil/cisplatinum in recurrent cervical cancer. Acta Oncol 1990, 29(1):25-28.
56. Bonomi P., Blessing J., Ball H., Hanjani P., DiSaia P.J. A phase II evaluation of cisplatin and 5-fluorouracil in patients with advanced squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol 1989, 34(3):357-359.
57. Benjapibal M., Thirapakawong C., Leelaphatanadit C., Therasakvichya S., Inthasorn P. A pilot phase II study of capecitabine plus cisplatin in the treatment of recurrent carcinoma of the uterine cervix. Oncology 2007, 72:33-38.
58. Errihani H., M'rabti H., Ismaili N., et al. Phase II trial of capecitabine and cisplatin in advanced, persistent, or recurrent carcinoma of the cervix. Int J Gynecol Cancer 2011, 21(2):373-377.
59. Daghestani A.N., Hakes T.B., Lynch G., Lewis J.L. Cervix carcinoma: treatment with combination cisplatin and bleomycin. Gynecol Oncol 1983, 16(3):334-339.
60. Eralp Y., Saip P., Sakar B., Tas F., Aydiner A., Topuz E. Efficacy of cisplatin and cyclophosphamide combination for recurrent and metastatic carcinoma of the uterine cervix. Eur J Gynaecol Oncol 2003, 24:323-326.
61. Chitapanarux I., Tonusin A., Sukthomya V., Charuchinda C., Pukanhapan N., Lorvidhaya V. Phase II clinical study of irinotecan and cisplatin as first-line chemotherapy in metastatic or recurrent cervical cancer. Gynecol Oncol 2003, 89:402-407.
62. Muggia F.M., Blessing J.A., McGehee R., Monk B.J. Cisplatin and irinotecan in squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol 2004, 94(2):483-487.
63. Nagourney R.A., Link J.S., Blitzer J.B., Forsthoff C., Evans S.S. Gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed breast cancer patients. J Clin Oncol 2000, 18:2245-2249.
64. Tewari K.S., Monk B.J. The rationale for the use of non-platinum chemotherapy doublets for metastatic and recurrent cervical carcinoma. Clin Adv Hematol Oncol 2010, 8(2):108-115.
65. Lorvidhaya V., Kamnerdsupaphon P., Chitapanarux I., Sukthomya V., Tonusin A. Cisplatin and gemcitabine in patients with metastatic cervical cancer. Gan To Kagaku Ryoho 2004, 31:1057-1062.
66. Dueñas-Gonzalez A., Lopez-Graniel C., Gonzalez A., et al. A phase II study of gemcitabine and cisplatin combination as induction chemotherapy for untreated locally advanced cervical carcinoma. Ann Oncol 2001, 12(4):541-547.
67. Matulonis U.A., Campos S., Duska L., et al. Phase I/II dose finding study of combination cisplatin and gemcitabine in patients with recurrent cervix cancer. Gynecol Oncol 2006, 103:160-164.
68. Brewer C.A., Blessing J.A., Nagourney R.A., McMeekin D.S., Lele S., Zweizig S.L. Cisplatin plus gemcitabine in previously treated squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol 2006, 100(2):385-388.
69. Monk B.J., Sill M.W., McMeekin D.S., et al. Phase III trial of four cisplatincontaining doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 2009, 27:4649-4655.
70. Coleman R.E., Clarke J.M., Slevin M.L., et al. A phase II study of ifosfamide and cisplatin chemotherapy for metastatic or relapsed carcinoma of the cervix. Cancer Chemother Pharmacol 1990, 27:52-54.
71. Omura G.A., Blessing J.A., Vaccarello L., et al. A randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 1997, 15:165-167.
72. Fiorica J., Holloway R., Ndubisi B., et al. Phase II trial of topotecan and cisplatin in persistent or recurrent squamous and nonsquamous carcinomas of the cervix. Gynecol Oncol 2002, 85:89-94.
73. Long H.J., Bundy B.N., Grendys E.C. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group study. J Clin Oncol 2005, 23(21):4626-4633.
74. Brave M., Dagher R., Farrell A., et al. Topotecan in combination with cisplatin for the treatment of stage IVB, recurrent, or persistent cervical cancer. Oncology (Williston Park) 2006, 20(1401-1404):1410.
75. Rose P.G., Blessing J.A., Gershenson D.M., McGehee R. Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 1999, 17(9):2676-2680.
76. Papadimitriou C.A., Sarris K., Moulopoulos L.A., et al. Phase II trial of paclitaxel and cisplatin in metastatic and recurrent carcinoma of the uterine cervix. J Clin Oncol 1999, 17(3):761-766.
77. Moore D.H., Blessing J.A., McQuellon R.P., et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol 2004, 22(15):3113-3119.
78. Gebbia V., Caruso M., Testa A., et al. Vinorelbine and cisplatin for the treatment of recurrent and/or metastatic carcinoma of the uterine cervix. Oncology 2002, 63(1):31-37.
79. Morris M., Blessing J.A., Monk B.J., McGehee R., Moore D.H. Phase II study of cisplatin and vinorelbine in squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 2004, 22(16):3340-3344.
80. Goedhals L., Falkson G., Smith B. Vinorelbine and cisplatin in advanced squamous cell carcinoma of the cervix: the South African experience. Anticancer Res 2005, 25(3c):2489-2492.
81. Monk B.J., Sill M.W., McMeekin D.S., et al. Phase III trial of four cisplatin containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 2009, 27:4649-4655.
82. Alberts D.S., Martimbeau P.W., Surwit E.A., Oishi N. Mitomycin-C, bleomycin, vincristine, and cis-platinum in the treatment of advanced, recurrent squamous cell carcinoma of the cervix. Cancer Clin Trials 1981, 4(3):313-316.
83. Weiner S.A., Aristizabal S., Alberts D.S., Surwit E.A., Deatherage-Deuser K. A phase II trial of mitomycin, vincristine, bleomycin, and cisplatin (MOBP) as neoadjuvant therapy in high-risk cervical carcinoma. Gynecol Oncol 1988, 30(1):1-6.
84. Shimizu Y., Akiyama F., Umezawa S., Ishiya T., Utsugi K., Hasumi K. Combination of consecutive low-dose cisplatin with bleomycin, vincristine, and mitomycin for recurrent cervical carcinoma. J Clin Oncol 1998, 16(5):1869-1878.
85. Rustin G.J., Newlands E.S., Southcott B.M., Singer A. Cisplatin, vincristine, methotrexate and bleomycin (POMB) as initial or palliative chemotherapy for carcinoma of the cervix. Br J Obstet Gynaecol 1987, 94(12):1205-1211.
86. Buxton E.J., Meanwell C.A., Hilton C., et al. Combination bleomycin, ifosfamide, and cisplatin chemotherapy in cervical cancer. J Natl Cancer Inst 1989, 81(5):359-361.
87. Bloss J.D., Blessing J.A., Behrens B.C., Mannel R.S., Rader J.S., Sood A.K., et al. Randomized trial of cisplatin and ifosfamide with or without bleomycin in squamous carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol 2002, 20(7):1832-1837.
88. Cadron I., Jakobsen A., Vergote I. Report of an early stopped randomized trial comparing cisplatin vs. cisplatin/ifosfamide/ 5-fluorouracil in recurrent cervical cancer. Gynecol Obstet Invest 2005, 59(3):126-129.
89. Long H.J., Cross W.G., Wieand H.S., et al. Phase II trial of methotrexate, vinblastine, doxorubicin, and cisplatin in advanced/recurrent carcinoma of the uterine cervix and vagina. Gynecol Oncol 1995, 57(2):235-239.
90. Papadimitriou C.A., Dimopoulos M.A., Giannakoulis N., et al. A phase II trial of methotrexate, vinblastine, doxorubicin, and cisplatin in the treatment of metastatic carcinoma of the uterine cervix. Cancer 1997, 79(12):2391-2395.
91. Zanetta G., Fei F., Parma G., et al. Paclitaxel, ifosfamide and cisplatin (TIP) chemotherapy for recurrent or persistent squamous-cell cervical cancer. Ann Oncol 1999 Oct, 10(10):1171-1174.
92. Dimopoulos M.A., Papadimitriou C.A., Sarris K., et al. Combination of ifosfamide, paclitaxel, and cisplatin for the treatment of metastatic and recurrent carcinoma of the uterine cervix: a phase II study of the Hellenic Cooperative Oncology Group. Gynecol Oncol 2002, 85(3):476-478.
93. Choi C.H., Kim T.J., Lee S.J., et al. Salvage chemotherapy with a combination of paclitaxel, ifosfamide, and cisplatin for the patients with recurrent carcinoma of the uterine cervix. Int J Gynecol Cancer 2006, 16(3):1157-1164.
94. Mountzios G., Dimopoulos M.A., Bamias A., et al. Randomized multicenter phase II trial of cisplatin and ifosfamide with or without paclitaxel in recurrent or metastatic carcinoma of the uterine cervix: a Hellenic Cooperative Oncology Group (HeCOG) study. Ann Oncol 2009, 20:1362-1368.
95. Downs L.S., Chura J.C., Argenta P.A., et al. Ifosfamide, paclitaxel, and carboplatin, a novel triplet regimen for advanced, recurrent, or persistent carcinoma of the cervix: a phase II trial. Gynecol Oncol 2011, 120(2):265-269.
96. Tewari K.S., Monk B.J. Recent achievements and future developments in advanced and recurrent cervical cancer: trials of the Gynecologic Oncology Group. Semin Oncol 2009, 36:170-180.
97. Ozols R.F., Bundy B.N., Greer B.E., et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003, 21:3194-3200.
98. Sit A.S., Kelley J.L., Gallion H.H., et al. Paclitaxel and carboplatin for recurrent or persistent cancer of the cervix. Cancer Invest 2004, 22:368-373.
99. Tinker A.V., Bhagat K., Swenerton K.D., Hoskins P.J. Carboplatin and paclitaxel for advanced and recurrent cervical carcinoma: the British Columbia Cancer Agency experience. Gynecol Oncol 2005, 98:54-58.
100. Pectasides D., Fountzilas G., Papaxoinis G., et al. Carboplatin and paclitaxel in metastatic or recurrent cervical cancer. Int J Gynecol Cancer 2009, 19:777-781.
101. Nagao S., Fujiwara K., Oda T., et al. Combination chemotherapy of docetaxel and carboplatin in advanced or recurrent cervix cancer. Gynecol Oncol 2005, 96(3):805-809.
102. Symonds R., Davidson S., Chan S., Reed N., McMahon T., Paul J. SCOTCERV: a phase II trial of docetaxel and gemcitabine as second-line chemotherapy in cervical cancer. J Clin Oncol (ASCO Annual Meeting Abstracts) 2007, 25:5548.
103. Tebbutt N., Rischin D., Quinn M., et al. A phase II trial of carboplatin and etoposide for relapsed or metastatic carcinoma of the cervix. Aust N Z J Obstet Gynaecol 1998, 38:87-90.
104. Hainsworth J.D., Burris H.A., Meluch A.A., Baker M.N., Morrissey L.H., Greco F.A. Paclitaxel, carboplatin, and long-term continuous infusion of 5-fluorouracil in the treatment of advanced squamous and other selected carcinomas: results of a phase II trial. Cancer 2001, 92(3):642-649.
105. Cooper R.A., Wilks D.P., Logue J.P., et al. High tumor angiogenesis is associated with poorer survival in carcinoma of the cervix treated with radiotherapy. Clin Cancer Res 1998, 4:2795-2800.
106. Randall L.M., Monk B.J., Darcy K.M., et al. Markers of angiogenesis in high-risk, early-stage cervical cancer: a Gynecologic Oncology Group study. Gynecol Oncol 2009, 112:583-589.
107. Liao S.Y., Darcy K.M., Randall L.M., et al. Prognostic relevance of carbonic anhydrase-IX in high-risk, early-stage cervical cancer: a Gynecologic Oncology Group Study. Gynecol Oncol 2010, 116(3):452-458.
108. Gaffney D.K., Haslam D., Tsodikov A., et al. Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) negatively affect overall survival in carcinoma of the cervix treated with radiotherapy. Int J Radiat Oncol Biol Phys 2003, 56:922-928.
109. Loncaster J.A., Cooper R.A., Logue J.P., Davidson S.E., Hunter R.D., West C.M. Vascular endothelial growth factor (VEGF) expression is a prognostic factor for radiotherapy outcome in advanced carcinoma of the cervix. Br J Cancer 2000, 83:620-625.
110. Cheng W.F., Chen C.A., Lee C.N., Wei L.H., Hsieh F.J., Hsieh C.Y. Vascular endothelial growth factor and prognosis of cervical carcinoma. Am J Obstet Gynecol 2000, 96:721-726.
111. Wright J.D., Viviano D., Powell M.A., et al. Bevacizumab combination therapy in heavily pretreated, recurrent cervical cancer. Gynecol Oncol 2006, 103:489-493.
112. Monk B.J., Sill M.W., Burger R.A., Gray H.J., Buekers T.E., Roman L.D. Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol 2009, 27:1069-1074.
113. Tewari K.S., Monk B.J. American Society of Clinical Oncology 2011 Annual Meeting update: summary of selected gynecologic cancer abstracts. Gynecol Oncol 2011, 122(2):209-212.
114. del Campo J.M., Prat A., Gil-Moreno A., Pérez J., Parera M. Update on novel therapeutic agents for cervical cancer. Gynecol Oncol 2008, 110:S72-S76.
115. Araújo A.P., Catarino R., Ribeiro R., Pereira D., Pinto D., Medeiros R. Epidermal growth factor genetic variation associated with advanced cervical cancer in younger women. Am J Clin Oncol 2011 Feb 22, [Epub ahead of print].
116. Bellone S., Frera G., Landolfi G., et al. Overexpression of epidermal growth factor type-1 receptor (EGF-R1) in cervical cancer: implications for cetuximab-mediated therapy in recurrent/metastatic disease. Gynecol Oncol 2007, 106:513-520.
117. Hertlein L., Lenhard M., Kirschenhofer A., et al. Cetuximab monotherapy in advanced cervical cancer: a retrospective study with five patients. Arch Gynecol Obstet 2011, 283(1):109-113.
118. Farley J., Sill M.W., Birrer M., et al. Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: a Gynecologic Oncology Group study. Gynecol Oncol 2011, 121(2):303-308.
119. Kurtz E., Hardy-Bessard A.C., Deslandres M., et al. Cetuximab, topotecan and cisplatin for the treatment of advanced cervical cancer: a phase II GINECO trial. Gynecol Oncol 2009, 113:16-20.
120. Kang S., Kim H.S., Seo S.S., Park S.Y., Sidransky D., Dong S.M. Inverse correlation between RASSF1A hypermethylation, KRAS and BRAF mutations in cervical adenocarcinoma. Gynecol Oncol 2007, 105:662-666.
121. Schilder R.J., Sill M.W., Lee Y.C., Mannel R. A phase II trial of erlotinib in recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Int J Gynecol Cancer 2009, 19:929-933.
122. Goncalves A., Fabbro M., Lhommé C., et al. A phase II trial to evaluate gefitinib as second- or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer. Gynecol Oncol 2008, 108:42-46.
123. Monk B.J., Mas Lopez L., Zarba J.J., et al. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. J Clin Oncol 2010, 28(22):3562-3569.
124. Mackay H.J., Tinker A., Winquist E., et al. A phase II study of sunitinib in patients with locally advanced or metastatic cervical carcinoma: NCIC CTG Trial IND.184. Gynecol Oncol 2010, 116(2):163-167.
125. Candelaria M., Arias-Bonfill D., Chávez-Blanco A., et al. Lack in efficacy for imatinib mesylate as second-line treatment of recurrent or metastatic cervical cancer expressing platelet-derived growth factor receptor alpha. Int J Gynecol Cancer 2009, 19(9):1632-1637.
126. Richter C.E., Cocco E., Bellone S. Primary cervical carcinoma cell lines overexpress epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a fully human monoclonal anti-EpCAM antibody. Int J Gynecol Cancer 2010, 20(9):1440-1447.
127. Coronel J., Cetina L., Pacheco I., et al. A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results. Med Oncol 2011, 28(Suppl 1):S540-S546.
128. Moore D.H., Tian C., Monk B.J., Long H.J., Omura G.A., Bloss J.D. Prognostic factors for response to cisplatin-based chemotherapy in advanced cervical carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol 2010, 116(1):44-49.
129. Federico C., Alleyn J., Dola C., et al. Relationship among age, race, medical funding, and cervical cancer survival. J Natl Med Assoc 2010, 102(3):199-205.
130. Nagy V.M., Buiga R., Brie I., et al. Expression of VEGF, VEGFR, EGFR, COX-2 and MVD in cervical carcinoma, in relation with the response to radio-chemotherapy. Rom J Morphol Embryol 2011, 52(1):53-59.
131. Min L., Dong-Xiang S., Xiao-Tong G., Ting G., Xiao-Dong C. Clinicopathological and prognostic significance of Bmi-1 expression in human cervical cancer. Acta Obstet Gynecol Scand 2011, 90(7):737-745.
132. Noordhuis M.G., Eijsink J.J., Roossink F., et al. Prognostic cell biological markers in cervical cancer patients primarily treated with (chemo)radiation: a systematic review. Int J Radiat Oncol Biol Phys 2011, 79(2):325-334.
133. Sharma A., Rajappa M., Satyam A., Sharma M. Oxidant/anti-oxidant dynamics in patients with advanced cervical cancer: correlation with treatment response Mol Cell Biochem. 2010, 341(1-2):65-72.
134. Sharma A., Rajappa M., Satyam A., Sharma M. Cytokines (TH1 and TH2) in patients with advanced cervical cancer undergoing neoadjuvant chemoradiation: correlation with treatment response. Int J Gynecol Cancer 2009, 19(7):1269-1275.
135. Harima Y., Ikeda K., Utsunomiya K., et al. Identification of genes associated with progression and metastasis of advanced cervical cancers after radiotherapy by cDNA microarray analysis. Int J Radiat Oncol Biol Phys 2009, 75(4):1232-1239.
136. Hu X., Schwarz J.K., Lewis J.J.S., et al. A microRNA expression signature for cervical cancer prognosis. Cancer Res 2010, 70(4):1441-1448.
137. Suprasert P., Charoenkwan K., Cheewakriangkrai C. Outcomes of advanced and recurrent cervical cancer treated with cisplatin and generic topotecan: retrospective analysis in a tertiary care hospital in Thailand. J Gynecol Oncol 2010, 21(4):237-240.
138. Burnett A.F., Roman L.D., Garcia A.A., Muderspach L.I., Brader K.R., Morrow C.P. A phase II study of gemcitabine and cisplatin in patients with advanced, persistent, or recurrent squamous cell carcinoma of the cervix. Gynecol Oncol 2000, 76(1):63-66.
139. Tinker A.V., Bhagat K., Swenerton K.D., Hoskins P.J. Carboplatin and paclitaxel for advanced and recurrent cervical carcinoma: the British Columbia Cancer Agency experience. Gynecol Oncol 2005, 98(1):54-58.
140. Takekida S., Fujiwara K., Nagao S., et al. Phase II study of combination chemotherapy with docetaxel and carboplatin for locally advanced or recurrent cervical cancer. Int J Gynecol Cancer 2010, 20(9):1563-1568.
141. Secord A.A., Havrilesky L.J., Carney M.E., et al. Weekly low-dose paclitaxel and carboplatin in the treatment of advanced or recurrent cervical and endometrial cancer. Int J Clin Oncol 2007, 12(1):31-36.
142. Symonds R.P., Davidson S.E., Chan S., et al. SCOTCERV: a phase II trial of docetaxel and gemcitabine as second line chemotherapy in cervical cancer. Gynecol Oncol 2011, 123(1):105-109.
143. Wagenaar H.C., Pecorelli S., Mangioni C., et al. Phase II study of mitomycin-C and cisplatin in disseminated, squamous cell carcinoma of the uterine cervix. A European Organization for Research and Treatment of Cancer (EORTC) Gynecological Cancer Group study. Eur J Cancer 2001, 37(13):1624-1628.
144. Tiersten A.D., Selleck M.J., Hershman D.L., et al. Phase II study of topotecan and paclitaxel for recurrent, persistent, or metastatic cervical carcinoma. Gynecol Oncol 2004, 92(2):635-638.
145. Umesaki N., Fujii T., Nishimura R., et al. Phase II study of irinotecan combined with mitomycin-C for advanced or recurrent squamous cell carcinoma of the uterine cervix: the JGOG study. Gynecol Oncol 2004, 95(1):127-132.
146. Smith H.O., Jiang C.S., Weiss G.R., et al. Tirapazamine plus cisplatin in advanced or recurrent carcinoma of the uterine cervix: a Southwest Oncology Group study. Int J Gynecol Cancer 2006, 16(1):298-305.
147. Maluf F.C., Leiser A.L., Aghajanian C., et al. Phase II study of tirapazamine plus cisplatin in patients with advanced or recurrent cervical cancer. Int J Gynecol Cancer 2006, 16(3):1165-1171.
148. Ramm K., Vergote I.B., Kaern J., Tropé C.G. Bleomycin-ifosfamide-cis-platinum (BIP) in pelvic recurrence of previously irradiated cervical carcinoma: a second look. Gynecol Oncol 1992, 46(2):203-207.
149. Kumar L., Pokharel Y.H., Kumar S., Singh R., Rath G.K., Kochupillai V. Single agent versus combination chemotherapy in recurrent cervical cancer. J Obstet Gynaecol Res 1998, 24(6):401-409.
150. Murad A.M., Triginelli S.A., Ribalta J.C. Phase II trial of bleomycin, ifosfamide, and carboplatin in metastatic cervical cancer. J Clin Oncol 1994, 12(1):55-59.
151. Fanning J., Ladd C., Hilgers R.D. Cisplatin, 5-fluorouracil, and ifosfamide in the treatment of recurrent or advanced cervical cancer. Gynecol Oncol 1995, 56(2):235-238.
152. Hainsworth J.D., Meluch A.A., McClurkan S. Induction paclitaxel, carboplatin, and infusional 5-FU followed by concurrent radiation therapy and weekly paclitaxel/carboplatin in the treatment of locally advanced head and neck cancer: a phase II trial of the Minnie Pearl Cancer Research Network. Cancer J 2002, 8(4):311-321.